Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome
Clinical trial NCT05137496 · UNKNOWN
Trial details
- NCT number
- NCT05137496
- Sponsor
- Beijing Friendship Hospital
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-06-01
- Primary completion
- 2023-06-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.